Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 10/2019

01-10-2019 | Human Immunodeficiency Virus | Original Paper

Risk Behavior Not Associated with Self-Perception of PrEP Candidacy: Implications for Designing PrEP Services

Authors: Lu Xie, Yumeng Wu, Siyan Meng, Jianhua Hou, Rong Fu, Huang Zheng, Na He, Min Wang, Kathrine Meyers

Published in: AIDS and Behavior | Issue 10/2019

Login to get access

Abstract

In a study of sexually-active HIV-negative men who have sex with men (MSM) in China, we compared behavioral indication for pre-exposure prophylaxis (PrEP) based on risk criteria to self-perception of PrEP candidacy (SPC) and explored factors associated with SPC. Of 708 MSM surveyed, 323 (45.6%) were behaviorally-indicated for PrEP, among whom 42.1% self-perceived as appropriate PrEP candidates. In a multivariable model we found no association between sexual behavior nor HIV risk perception and SPC but found that higher perceived benefits of PrEP, increased frequency of HIV testing, and low condom use self-efficacy were positively-associated with SPC. In a sub-analysis restricted to MSM behaviorally-indicated for PrEP, relationship-factors were also significant. Our findings suggest that PrEP implementers should look beyond risk criteria to consider shared decision-making tools that support individuals to assess whether they are appropriate PrEP candidates based on their existing HIV prevention strategies, sexual health goals, and relationship dynamics.
Appendix
Available only for authorised users
Literature
1.
Sullivan P, Smith K, Mera-Giler R, Siddiqi A, Gunnels B, Harris N, et al. The impact of pre-exposure prophylaxis with TDF/FTC on HIV diagnoses, 2012–2016, United States. Abstract number: LBPEC036. 22nd International AIDS Conference (AIDS 2018); Amsterdam, the Netherlands 2018.
2.
San Francisco Department of Public Health. HIV Epidemiology Annual Report 2017. Population Health Division SF. 2017.
3.
The New York City Department of Health and Mental Hygiene. Bureau of Sexually Transmitted Disease Control Quarterly Report (2017: 4th Quarter). 2018.
4.
Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018;5(11):e629–37.PubMed
5.
Brown A, Kirwan P, Chau C, Khawam J, Gill N, Delpech V. Towards elimination of HIV transmission, AIDS and HIV-related deaths in the UK. In: Public Health England, Editor. 2017.
6.
Coleman R. Setting the scene, setting the targets. The Joint United Nations Programme on HIV/AIDS prevention targets of 2016 and estimating global pre-exposure prophylaxis targets. CSIRO Sex Health. 2018;15(6):485–8.
7.
Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone A. Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect. 2013;89(3):207–11.PubMed
8.
Allen E, Gordon A, Krakower D, Hsu K. HIV preexposure prophylaxis for adolescents and young adults. Curr Opin Pediatr. 2017;29(4):399–406.PubMedPubMedCentral
9.
Calabrese SK, Underhill K. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “Truvada Whores”. Am J Public Health. 2015;105(10):1960–4.PubMedPubMedCentral
10.
Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using PrEP among black and white men and transgender women who have sex with men. AIDS Behav. 2017;21(5):1236–46.PubMedPubMedCentral
11.
Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.PubMedPubMedCentral
12.
Grov C, Whitfield THF, Rendina HJ, Ventuneac A, Parsons JT. Willingness to take PrEP and potential for risk compensation among highly sexually active gay and bisexual men. AIDS Behav. 2015;19(12):2234–44.PubMedPubMedCentral
13.
Haire BG. Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence—a narrative review. HIV/AIDS (Auckl). 2015;7:241–9.PubMedCentral
14.
Plotzker R, Seekaew P, Jantarapakde J, Pengnonyang S, Trachunthong D, Linjongrat D, et al. Importance of risk perception: predictors of PrEP acceptance among Thai MSM and TG women at a community-based health service. J Acquir Immune Defic Syndr. 2017;76(5):473–81.PubMed
15.
Underhill K, Guthrie KM, Colleran C, Calabrese SK, Operario D, Mayer KH. Temporal fluctuations in behavior, perceived HIV risk, and willingness to use pre-exposure prophylaxis (PrEP). Arch Sex Behav. 2018;47(7):2109–21.PubMedPubMedCentral
16.
Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.PubMedPubMedCentral
17.
Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59(5):463–8.PubMed
18.
Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12(1):38–48.PubMed
19.
Parsons JT, Rendina HJ, Lassiter JM, Whitfield TH, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States: the motivational PrEP cascade. J Acquir Immune Defic Syndr. 2017;74(3):285.PubMedPubMedCentral
20.
21.
Peng P, Su S, Fairley CK, Chu M, Jiang S, Zhuang X, et al. A global estimate of the acceptability of pre-exposure prophylaxis for HIV among men who have sex with men: a systematic review and meta-analysis. AIDS Behav. 2018;22(4):1063–74.PubMed
22.
Yi S, Tuot S, Mwai GW, Ngin C, Chhim K, Pal K, et al. Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low-and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc. 2017;20(1):21580.PubMedPubMedCentral
23.
Bourne A, Cassolato M, Thuan Wei CK, Wang B, Pang J, Lim SH, et al. Willingness to use pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Malaysia: findings from a qualitative study. J Int AIDS Soc. 2017;20(1):21899.PubMedPubMedCentral
24.
To KW, Lee SS. HIV pre-exposure prophylaxis in South East Asia: a focused review on present situation. Int J Infect Dis. 2018;77:113–7.PubMed
25.
Chakrapani V, Newman P, Shunmugam M, Mengle S, Varghese J, Nelson R, et al. Acceptability of HIV Pre-exposure prophylaxis (prep) and implementation challenges among men who have sex with men in India: a qualitative investigation. AIDS Patient Care STDs. 2015;10:569–77.
26.
Wang X, Bourne A, Liu P, Sun J, Cai T, Mburu G, et al. Understanding willingness to use oral pre-exposure prophylaxis for HIV prevention among men who have sex with men in China. PLoS ONE. 2018;13(6):e0199525.PubMedPubMedCentral
27.
Ding Y, Yan H, Ning Z, Cai X, Yang Y, Pan R, et al. Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai China. Biosci Trends. 2016;10(2):113–9.PubMed
28.
Draper BL, Oo ZM, Thein ZW, Aung PP, Veronese V, Ryan C, et al. Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. J Int AIDS Soc. 2017;20(1):21885.PubMedPubMedCentral
29.
Hoagland B, De Boni RB, Moreira RI, Madruga JV, Kallas EG, Goulart SP, et al. Awareness and willingness to use pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women in Brazil. AIDS Behav. 2017;21(5):1278–87.PubMed
30.
Jackson T, Huang A, Chen H, Gao X, Zhong X, Zhang Y. Cognitive, psychosocial, and sociodemographic predictors of willingness to use HIV pre-exposure prophylaxis among Chinese men who have sex with men. AIDS Behav. 2012;16(7):1853–61.PubMed
31.
Young I, Li J, McDaid L. Awareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV prevention. PLoS ONE. 2013;8(5):e64038.PubMedPubMedCentral
32.
Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77–83.PubMedPubMedCentral
33.
Holt M, Murphy DA, Callander D, Ellard J, Rosengarten M, Kippax SC, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012;88(4):258–63.PubMed
34.
Meyers K, Wu Y, Qian H, Sandfort T, Huang X, Xu J, et al. Interest in long-acting injectable PrEP in a cohort of men who have sex with men in China. AIDS Behav. 2018;22(4):1217–27.PubMedPubMedCentral
35.
Eaton LA, Driffin DD, Smith H, Conway-Washington C, White D, Cherry C. Psychosocial factors related to willingness to use pre-exposure prophylaxis for HIV prevention among Black men who have sex with men attending a community event. Sex Health. 2014;11(3):244–51.PubMedPubMedCentral
36.
37.
Gallagher T, Link L, Ramos M, Bottger E, Aberg J, Daskalakis D. Self-perception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York City. LGBT Health. 2014;1(3):218–24.PubMed
38.
Lockard A, Rosenberg ES, Sullivan PS, Kelley CF, Serota DP, Rolle CM, et al. Contrasting self-perceived need and guideline-based indication for HIV pre-exposure prophylaxis among Young, Black Men who have sex with men offered pre-exposure prophylaxis in Atlanta Georgia. AIDS Patient Care STDs. 2019;33(3):112–9.PubMedPubMedCentral
39.
Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in pre-exposure prophylaxis among men who have sex with men at risk for HIV-infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr (1999). 2015;68(4):439.
40.
Cui Y, Guo W, Li D, Wang L, Shi CX, Brookmeyer R, et al. Estimating HIV incidence among key affected populations in China from serial cross-sectional surveys in 2010–2014. J Int AIDS Soc. 2016;19(1):20609.PubMedPubMedCentral
41.
Zhang W, Xu JJ, Zou H, Zhang J, Wang N, Shang H. HIV incidence and associated risk factors in men who have sex with men in Mainland China: an updated systematic review and meta-analysis. Sex Health. 2016;13(4):373–82.
42.
Wang QQ, Chen XS, Yin YP, Liang GJ, Zhang RL, Jiang N, et al. HIV prevalence, incidence and risk behaviours among men who have sex with men in Yangzhou and Guangzhou, China: a cohort study. J Int AIDS Soc. 2014;17:18849.PubMedPubMedCentral
43.
Mao X, Wang Z, Hu Q, Huang C, Yan H, Wang Z, et al. HIV incidence is rapidly increasing with age among young men who have sex with men in China: a multicentre cross-sectional survey. HIV Med. 2018;19(8):513–22.PubMedCentral
44.
AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention. [Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)]. Zhonghua nei ke za zhi. 2018;57(12):867–84.
45.
46.
Li L, Jiang Z, Song W, Ding Y, Xu J, He N. [Chinese] Constructing an HIV risk assessment tool for MSM using the Delphi method. Chin J Epidemiol. 2017;38(10):1426–30.
47.
IBM. SPSS Statistics, Version 22.0. New York: IBM Corp. 2014.
48.
Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15:1–8.
49.
Dubov A, Galbo P Jr, Altice FL, Fraenkel L. Stigma and shame experiences by MSM who take PrEP for HIV prevention: a qualitative study. Am J Mens Health. 2018;12(6):1843–54.PubMedPubMedCentral
50.
Jaspal R, Nerlich B. Polarised press reporting about HIV prevention: social representations of pre-exposure prophylaxis in the UK press. Health (London). 2017;21(5):478–97.PubMed
51.
Brooks RA, Landrian A, Nieto O, Fehrenbacher A. Experiences of anticipated and enacted pre-exposure prophylaxis (PrEP) stigma among Latino MSM in Los Angeles. AIDS Behav. 2019;23(7):1–10.
52.
Spieldenner A. PrEP whores and HIV prevention: the queer communication of HIV pre-exposure prophylaxis (PrEP). J Homosex. 2016;63(12):1685–97.PubMed
53.
54.
Wang X, Wu Z, Tang Z, Nong Q, Li Y. Promoting HIV testing with home self-test kit among men who have sex with men in China: a feasibility study. The Lancet. 2015;386:S68.
55.
Han L, Bien CH, Wei C, Muessig KE, Yang M, Liu F, et al. HIV self-testing among online MSM in China: implications for expanding HIV testing among key populations. J Acquir Immune Defic Syndr. 2014;67(2):216.PubMedPubMedCentral
56.
Tang W, Wei C, Cao B, Wu D, Li KT, Lu H, et al. Crowdsourcing to expand HIV testing among men who have sex with men in China: a closed cohort stepped wedge cluster randomized controlled trial. PLoS Med. 2018;15(8):e1002645.PubMedPubMedCentral
57.
Wei C, Yan H, Yang C, Raymond HF, Li J, Yang H, et al. Accessing HIV testing and treatment among men who have sex with men in China: a qualitative study. AIDS Care. 2014;26(3):372–8.PubMed
58.
Liu C, Mao J, Wong T, Tang W, Tso LS, Tang S, et al. Comparing the effectiveness of a crowdsourced video and a social marketing video in promoting condom use among Chinese men who have sex with men: a study protocol. BMJ Open. 2016;6(10):e010755.PubMedPubMedCentral
59.
Saberi P, Gamarel KE, Neilands TB, Comfort M, Sheon N, Darbes LA, et al. Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS ONE. 2012;7(11):e50061.PubMedPubMedCentral
60.
Gamarel KE, Golub SA. Intimacy motivations and pre-exposure prophylaxis (PrEP) adoption intentions among HIV-negative men who have sex with men (MSM) in romantic relationships. Ann Behav Med. 2014;49(2):177–86.
61.
Mitchell JW, Lee J-Y, Woodyatt C, Bauermeister J, Sullivan P, Stephenson R. HIV-negative male couples’ attitudes about pre-exposure prophylaxis (PrEP) and using PrEP with a sexual agreement. AIDS Care. 2016;28(8):994–9.PubMedPubMedCentral
62.
Lancki N, Almirol E, Alon L, McNulty M, Schneider J. PrEP guidelines have low sensitivity for identifying seroconverters in a sample of Young Black men who have sex with men in Chicago. AIDS. 2018;32(3):383–92.PubMed
63.
64.
65.
Dubov A, Altice FL, Fraenkel L. An information–motivation–behavioral skills model of PrEP uptake. AIDS Behav. 2018;22(11):3603–16.PubMed
66.
Bitton A, Gaziano T. The Framingham Heart Study’s impact on global risk assessment. Prog Cardiovasc Dis. 2010;53(1):68–78.PubMedPubMedCentral
67.
Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J. 2007;83(982):509–17.PubMedPubMedCentral
68.
Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343:d7163.PubMedPubMedCentral
69.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMed
70.
Hoots BE, Finlayson T, Nerlander L, Paz-Bailey G, Group NHBSS, Wortley P, et al. Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men—20 US cities, 2014. Clin Infect Dis. 2016;63(5):672–7.PubMed
71.
Blumenthal J, Jain S, Mulvihill E, Sun S, Hanashiro M, Ellorin E, et al. Perceived versus calculated HIV risk: Implications for Pre-exposure prophylaxis uptake in a randomized trial of men who have sex with men. J Acquir Immune Defic Syndr. 9000; Publish Ahead of Print.
72.
Barry MJ, Edgman-Levitan S. Shared decision making—the pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1.PubMed
Metadata
Title
Risk Behavior Not Associated with Self-Perception of PrEP Candidacy: Implications for Designing PrEP Services
Authors
Lu Xie
Yumeng Wu
Siyan Meng
Jianhua Hou
Rong Fu
Huang Zheng
Na He
Min Wang
Kathrine Meyers
Publication date
01-10-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 10/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02587-5

Other articles of this Issue 10/2019

AIDS and Behavior 10/2019 Go to the issue

Original Paper

Important Roles of Health Professionals in Maternal HIV Disclosure Among HIV-Infected Women in China

Original Paper

Community Levels of PrEP Use Among Men Who Have Sex with Men by Race/Ethnicity, San Francisco, 2017

Original Paper

Location of Pre-exposure Prophylaxis Services Across New York City Neighborhoods: Do Neighborhood Socio-demographic Characteristics and HIV Incidence Matter?

Original Paper

Expanding Knowledge About Implementation of Pre-exposure Prophylaxis (PrEP): A Methodological Review

Original Paper

Limited Knowledge and Lack of Screening for Acute HIV Infection at Primary Care Clinics in High-Prevalence Communities of New York City

Substantive Review

Suboptimal HIV Pre-exposure Prophylaxis Awareness and Willingness to Use Among Women Who Use Drugs in the United States: A Systematic Review and Meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits